Top Ten most popular articles on Pharmafile.com this week!
pharmafile | April 12, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile Britain’s cost effectiveness body NICE turned down Astellas’ Xtandi in prostate cancer.
Nevertheless our top story looked at Gilead’s announcement they would be laying off one fifth of their workforce. The news came as shares in Indivior plummeted by as much as 70% amid fraud allegations.
Otherwise two of our features found their way into the top ten. While Matt Fellows looked into real world evidence, Pharmafocus talked to Rebecca Pender whose daughter lived with the ultra-rare chromosome disorder Inv Dup Del 8p. Check out this week’s top 10 most popular stories on Pharmafile.com!
10. Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma will now be able to access Eisai and MSD’s Lenvima (lenvatinib) as a monotherapy via NHS Scotland, following a recommendation for the drug from the Scottish Medicines Consortium.
9. FDA approves Pfizer’s Ibrance for advanced male breast cancer
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in combination with an aromatase inhibitor or fulvestrant in the treatment of men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
8. ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
Viiv Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir and lamivudine) has secured FDA approval for the treatment of HIV-1 infection.
7. Patient Experience: Living with a rare chromosome disorder
Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 people worldwide. She recounts the struggle to secure a diagnosis, and how the experience shaped her attitude on how we confront rare disease
6. Feature: Protecting public health: Is real-world evidence the key?
In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need to deliver treatments and preventative therapies is a key concern for industry and national healthcare bodies. Matt Fellows explores how incorporating wider use of real-world evidence into these systems could be the solution we need.
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years old are at risk of fragility fractures as a result of osteoporosis, while, shockingly, three-quarters of this number have not received treatment for the condition.
4. BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to patients in England via the Cancer Drugs Fund (CDF) for the first-line treatment of untreated renal cell carcinoma (RCC), the most common form of kidney cancer.
3. NICE turns down Astellas’ Xtandi in prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for prostate cancer, it has emerged, meaning patients may need to wait until a later stage of their disease in order to access the drug on the health service.
2. Indivior shares fall by 70% after allegations of fraud
Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to the dangers of its Suboxone opioid addiction treatment.
1. Gilead to lay off one fifth of sales force
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents on two of the company’s older drugs.
Related Content
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …
Merck to acquire Harpoon Therapeutics for approximately $680m
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …
